Shots:
- Mammoth to receive $41M up front, $650M as future payments based upon the achievement of prespecified research, development & commercial milestones across 2 programs & is eligible to receive royalties on sales of any products
- The collaboration will bolster Vertex’s cell and genetic therapies capabilities with the addition of Mammoth’s ultra-small CRISPR systems to develop in vivo genome editing therapies for patients with serious diseases
- Mammoth’s CRISPR platform consists of a proprietary toolbox of novel ultra-compact Cas enzymes including Cas14 and Casɸ. The platform is designed to facilitate advanced delivery of in vivo gene-editing for genetic diseases
Click here to read full press release/ article | Ref: Businesswire | Image: Businesswire
The post Vertex Collaborates with Mammoth Biosciences to Develop In Vivo Gene-Editing Therapies for Genetic Diseases first appeared on PharmaShots.
